How the body processes an antifungal medicine during plasma exchange
Part of Infections clinical trials.
This study looks at how the body processes the antifungal medicine liposomal amphotericin B in people who are also having plasma exchange (a blood-filtering procedure). The goal is to understand if dosing needs to be adjusted when both treatments are used together.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old
- You must have an invasive fungal infection (a serious fungal infection in your body) or neutropenia (low white blood cells) with fever
- You are currently receiving liposomal amphotericin B (an antifungal medicine given through an IV)
- You are undergoing plasma exchange (a procedure that cleans your blood)
- You must be willing to sign a consent form agreeing to take part
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial looks at how a specific antifungal medicine, called liposomal amphotericin B, given over a longer period, helps prevent serious fungal infections in people undergoing treatment for cancer or receiving a stem cell transplant. It may be an option if you are at high risk for these infections.
This study looks at how a medicine called L-AmB (a type of amphotericin B, used to treat fungal infections) works in patients who are on ECMO. The goal is to find the right dose for people in your situation.
This trial tests a low dose of an antifungal medicine (liposomal amphotericin B) to prevent fungal infections in patients whose white blood cell counts are very low for more than a week. It may help patients who are at high risk for fungal infections and cannot take other antifungal drugs.
This trial tests a low dose of an antifungal medicine (liposomal amphotericin B) to prevent serious fungal infections in children whose immune system is weak after cancer treatment or a stem cell transplant. It's for kids aged 3 to 17 who are at high risk for these infections.
This study looks at how well liposomal amphotericin B works for treating serious fungal infections in people who have had an organ transplant. It aims to understand the treatment's effectiveness and safety in a real-world setting.
This trial tests whether amphotericin B can treat new fungal infections that develop in people with blood cancers even after they have taken preventive antifungal medicine. It may help patients who have a confirmed or suspected fungal infection while on that prevention.
Hear when a new Invasive Fungal Infections trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.